Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Hyatt Hotels Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Hyatt Hotels Corporation trades at $190.5 (market cap $18.00B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Hyatt Hotels Corporation's market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | H | |
|---|---|---|
Market Cap | $39.89B | $18.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $202.09 |
52-Week Low | $278.09 | $135.01 |
Enterprise Value | $38.15B | $21.84B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Hyatt Hotels Corp (H) trades at $191.14, up 0.63% on the day, with a bearish technical signal but mixed earnings performance. Recent quarters show beats on EPS estimates, though net income margin remains negative at -0.48%. The company announced expansion plans, including a new Hyatt Regency in Tucson, amid stable revenue around $7.1B. Cash flow trends indicate operational challenges, with net cash flow turning negative in 2025.
Outlook is cautious with analyst consensus tilted toward Hold (52.08%). Upside exists if operational efficiency improves and travel demand sustains, but risks include high debt levels and profitability pressures. The stock trades near the consensus price target of $197.30, suggesting limited near-term upside without fundamental catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
